Early serum tacrolimus levels predict long-term chronic kidney disease after liver transplantation
Autor(a) principal: | |
---|---|
Data de Publicação: | 2014 |
Outros Autores: | , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | MedicalExpress (São Paulo. Online) |
Texto Completo: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2358-04292014000300143 |
Resumo: | OBJECTIVE: To investigate risk factors for the development of chronic kidney disease and death two years postliver transplantation. METHOD: Associations between clinical and laboratory parameters and the development of chronic kidney disease and survival two years post-liver transplant were analyzed in a cohort of 148 adult patients with hepatic cirrhosis consecutively submitted to liver transplantation in a referral Brazilian center. RESULTS: Median age at liver transplantation was 56 (range, 20-73) years, and 105 (70.9%) patients were males. The prevalence of chronic kidney disease at two years post-liver transplantation was: stage 1 or no chronic kidney disease, 27.5%; stage 2, 33.8%; stage 3, 34.6%; stages 4-5, 4.7%. Four variables were independently associated with the stage of chronic kidney disease two years after liver transplantation: (i) age (at liver transplantation), (ii) male gender, (iii) median tacrolimus levels in the first three months post-liver transplantation, and (iv) median of serum creatinine in the first six months post-liver transplantation. Two variables showed independent association with death in two years post-liver transplantation: (i) stay in Intensive Care Unit for three or more days after the liver transplantation surgery and (ii) median of serum creatinine levels in the first six months post-liver transplantation equal or higher than 1.3 mg/dL. CONCLUSIONS: Administration of the lowest effective dose of tacrolimus and adoption of strategies to spare renal function are important measures to reduce the risk of late chronic kidney disease and death post-liver transplantation especially in high risk patients. |
id |
METC-1_f010e338e3d20c4f4e11c591cd4437e6 |
---|---|
oai_identifier_str |
oai:scielo:S2358-04292014000300143 |
network_acronym_str |
METC-1 |
network_name_str |
MedicalExpress (São Paulo. Online) |
repository_id_str |
|
spelling |
Early serum tacrolimus levels predict long-term chronic kidney disease after liver transplantationChronic kidney diseaseKidney dysfunctionLiver transplantationTacrolimus OBJECTIVE: To investigate risk factors for the development of chronic kidney disease and death two years postliver transplantation. METHOD: Associations between clinical and laboratory parameters and the development of chronic kidney disease and survival two years post-liver transplant were analyzed in a cohort of 148 adult patients with hepatic cirrhosis consecutively submitted to liver transplantation in a referral Brazilian center. RESULTS: Median age at liver transplantation was 56 (range, 20-73) years, and 105 (70.9%) patients were males. The prevalence of chronic kidney disease at two years post-liver transplantation was: stage 1 or no chronic kidney disease, 27.5%; stage 2, 33.8%; stage 3, 34.6%; stages 4-5, 4.7%. Four variables were independently associated with the stage of chronic kidney disease two years after liver transplantation: (i) age (at liver transplantation), (ii) male gender, (iii) median tacrolimus levels in the first three months post-liver transplantation, and (iv) median of serum creatinine in the first six months post-liver transplantation. Two variables showed independent association with death in two years post-liver transplantation: (i) stay in Intensive Care Unit for three or more days after the liver transplantation surgery and (ii) median of serum creatinine levels in the first six months post-liver transplantation equal or higher than 1.3 mg/dL. CONCLUSIONS: Administration of the lowest effective dose of tacrolimus and adoption of strategies to spare renal function are important measures to reduce the risk of late chronic kidney disease and death post-liver transplantation especially in high risk patients.Mavera Edições Técnicas e Científicas Ltda2014-06-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S2358-04292014000300143MedicalExpress v.1 n.3 2014reponame:MedicalExpress (São Paulo. Online)instname:Mavera Edições Científicas e Técnicas Ltda-MEinstacron:METC10.5935/MedicalExpress.2014.03.09info:eu-repo/semantics/openAccessBrandão,Vanessa B. A.Faria,Luciana C.Bicalho,Danielle M.Pereira,Fernando H.Lima,Agnaldo S.Ferrari,Teresa C. A.eng2016-06-06T00:00:00Zoai:scielo:S2358-04292014000300143Revistahttp://www.medicalexpress.net.brhttps://old.scielo.br/oai/scielo-oai.php||medicalexpress@me.net.br2358-04292318-8111opendoar:2016-06-06T00:00MedicalExpress (São Paulo. Online) - Mavera Edições Científicas e Técnicas Ltda-MEfalse |
dc.title.none.fl_str_mv |
Early serum tacrolimus levels predict long-term chronic kidney disease after liver transplantation |
title |
Early serum tacrolimus levels predict long-term chronic kidney disease after liver transplantation |
spellingShingle |
Early serum tacrolimus levels predict long-term chronic kidney disease after liver transplantation Brandão,Vanessa B. A. Chronic kidney disease Kidney dysfunction Liver transplantation Tacrolimus |
title_short |
Early serum tacrolimus levels predict long-term chronic kidney disease after liver transplantation |
title_full |
Early serum tacrolimus levels predict long-term chronic kidney disease after liver transplantation |
title_fullStr |
Early serum tacrolimus levels predict long-term chronic kidney disease after liver transplantation |
title_full_unstemmed |
Early serum tacrolimus levels predict long-term chronic kidney disease after liver transplantation |
title_sort |
Early serum tacrolimus levels predict long-term chronic kidney disease after liver transplantation |
author |
Brandão,Vanessa B. A. |
author_facet |
Brandão,Vanessa B. A. Faria,Luciana C. Bicalho,Danielle M. Pereira,Fernando H. Lima,Agnaldo S. Ferrari,Teresa C. A. |
author_role |
author |
author2 |
Faria,Luciana C. Bicalho,Danielle M. Pereira,Fernando H. Lima,Agnaldo S. Ferrari,Teresa C. A. |
author2_role |
author author author author author |
dc.contributor.author.fl_str_mv |
Brandão,Vanessa B. A. Faria,Luciana C. Bicalho,Danielle M. Pereira,Fernando H. Lima,Agnaldo S. Ferrari,Teresa C. A. |
dc.subject.por.fl_str_mv |
Chronic kidney disease Kidney dysfunction Liver transplantation Tacrolimus |
topic |
Chronic kidney disease Kidney dysfunction Liver transplantation Tacrolimus |
description |
OBJECTIVE: To investigate risk factors for the development of chronic kidney disease and death two years postliver transplantation. METHOD: Associations between clinical and laboratory parameters and the development of chronic kidney disease and survival two years post-liver transplant were analyzed in a cohort of 148 adult patients with hepatic cirrhosis consecutively submitted to liver transplantation in a referral Brazilian center. RESULTS: Median age at liver transplantation was 56 (range, 20-73) years, and 105 (70.9%) patients were males. The prevalence of chronic kidney disease at two years post-liver transplantation was: stage 1 or no chronic kidney disease, 27.5%; stage 2, 33.8%; stage 3, 34.6%; stages 4-5, 4.7%. Four variables were independently associated with the stage of chronic kidney disease two years after liver transplantation: (i) age (at liver transplantation), (ii) male gender, (iii) median tacrolimus levels in the first three months post-liver transplantation, and (iv) median of serum creatinine in the first six months post-liver transplantation. Two variables showed independent association with death in two years post-liver transplantation: (i) stay in Intensive Care Unit for three or more days after the liver transplantation surgery and (ii) median of serum creatinine levels in the first six months post-liver transplantation equal or higher than 1.3 mg/dL. CONCLUSIONS: Administration of the lowest effective dose of tacrolimus and adoption of strategies to spare renal function are important measures to reduce the risk of late chronic kidney disease and death post-liver transplantation especially in high risk patients. |
publishDate |
2014 |
dc.date.none.fl_str_mv |
2014-06-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2358-04292014000300143 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2358-04292014000300143 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.5935/MedicalExpress.2014.03.09 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Mavera Edições Técnicas e Científicas Ltda |
publisher.none.fl_str_mv |
Mavera Edições Técnicas e Científicas Ltda |
dc.source.none.fl_str_mv |
MedicalExpress v.1 n.3 2014 reponame:MedicalExpress (São Paulo. Online) instname:Mavera Edições Científicas e Técnicas Ltda-ME instacron:METC |
instname_str |
Mavera Edições Científicas e Técnicas Ltda-ME |
instacron_str |
METC |
institution |
METC |
reponame_str |
MedicalExpress (São Paulo. Online) |
collection |
MedicalExpress (São Paulo. Online) |
repository.name.fl_str_mv |
MedicalExpress (São Paulo. Online) - Mavera Edições Científicas e Técnicas Ltda-ME |
repository.mail.fl_str_mv |
||medicalexpress@me.net.br |
_version_ |
1754734596573888512 |